The review determined the efficacy of noninvasive ventilation (NIV) in patients with acute respiratory syndrome (ARDS). The authors concluded that evidence suggests NIV added to standard therapy is unlikely to have significant benefits in patients with ARDS. Robust conclusions were difficult given the clinical and methodological differences between the studies, in addition to the small number of included studies and the small data sets used.
Study selection
Randomised controlled trials (RCTs) were eligible for inclusion in the review. All the trials were prospective RCTs and included one multicentre study and two single-centre studies. Studies that compared NIV and standard therapy with standard therapy alone were eligible for inclusion in the review. All of the included studies used a full face mask (one study also used a nasal mask if the full face mask was not tolerated), two studies used noninvasive pressure support ventilation (NIPSV) and one study used continuous positive airway pressure (CPAP). Studies of patients with ARDS (for example, acute onset bilateral pulmonary infiltrates, PaO 2 /FiO 2 <200 on room air, and no clinical evidence of cardiac cause for pulmonary infiltrates) were eligible for inclusion in the review. No restrictions were placed on the proportion of patients with ARDS in a specific study. The ARDS populations included immunocompetent and immunosuppressed patients with pulmonary and extrapulmonary causes of ARDS; no study specifically included patients with ARDS. The primary outcomes of interest were need for endotracheal intubation and ICU mortality (or, if unavailable, hospital mortality).
The authors stated neither how the papers were selected for the review nor how many reviewers performed the selection.
Assessment of study quality
The studies appear to have been assessed in terms of allocation concealment and blinding. The authors did not state how many reviewers performed the validity assessment.
Data extraction
Two reviewers extracted data independently for the review. Differences in opinion were resolved by consensus or after consultation with a third reviewer. Risk difference (RD) and 95% confidence intervals (CI) were calculated for the clinical outcomes. Number needed to treat (NNT) was calculated.
Methods of synthesis
Studies were combined in a meta-analysis using a random-effects model. Summary estimates for the clinical outcomes were presented as risk reduction (RR) and absolute risk reduction (ARR) with their corresponding 95% CI. Statistical heterogeneity was assessed using the I 2 statistic (<50%), the Χ 2 test (p>0.05) and visual inspection of the forest plot.
